Medical Weight Loss with GLP-1 Medications: A Cardiologist's Guide to What You Need to Know

As a cardiologist practicing in San Diego, I’ve watched medical weight loss change a lot over the past few years. We have tools now that we didn’t have before, and the GLP-1 receptor agonists are the main reason. I want to share with you exactly what they can and cannot do, because the gap between the hope and the reality is where most patients get into trouble.

When patients ask me about these medications, I usually see a mix of hope and skepticism. They’ve tried diets, exercise programs, and other approaches, sometimes for decades, and they’ve been disappointed before. My job is to give you the full picture so you can decide whether these medications fit into your health.

The numbers are real. In clinical trials, patients using semaglutide (Wegovy) lost an average of 15% of their body weight over 68 weeks. Those using tirzepatide (Zepbound) lost more, averaging 18 to 20% over similar timeframes. For someone weighing 200 pounds, that’s 30 to 40 pounds of weight loss that holds. They aren’t magic, though, and you’ll get more out of them if you understand how they work and what to expect.

How GLP-1 medications work

Your body makes a hormone called glucagon-like peptide-1, or GLP-1. Your intestines release it after you eat, and it does several jobs at once. It tells your brain you’re full, slows how quickly food leaves your stomach, helps your pancreas release the right amount of insulin, and lowers the production of glucagon, a hormone that raises blood sugar.

Here’s the catch. Natural GLP-1 breaks down within minutes. The medications we prescribe are engineered versions that last much longer, usually about a week for the injectable forms we use for weight loss. You’re giving your body a steadier, stronger version of its own appetite control system.

After you inject one of these medications, a few things happen over the following days. Your appetite drops. A lot of my patients tell me they just stop thinking about food. The mental chatter about the next meal or snack quiets down. They feel satisfied with smaller portions, and rich, high-calorie foods stop appealing to them.

The stomach effect matters just as much. Food moves through your digestive system more slowly, so you stay full longer after eating. This isn’t about willpower. Your own regulatory systems are doing the work, which is why most patients describe it as easier than white-knuckling through hunger.

What your results will look like

When we start you on one of these medications, I want your expectations set right from the beginning. This isn’t the dramatic drop you’d see in the first week of a crash diet. You’ll typically lose 1 to 2 pounds per week, with some weeks heavier than others and some weeks flat or even up a little.

Most of the weight comes off in the first 6 to 8 months. After that the pace slows, but many patients keep losing small amounts over the following months. The part that’s historically been hardest in weight management is holding the loss, and that’s where these medications earn their keep. Once you reach your new weight, the medication helps you stay there.

I track more than the scale. We watch waist circumference, blood pressure, blood sugar, and cholesterol. Often the cardiovascular numbers improve before the weight changes dramatically. Your body composition shifts too. Patients usually lose fat while holding onto muscle, especially when they add resistance exercise.

Not everyone responds the same. About 15 to 20% of patients don’t get significant weight loss even at maximum doses. We call the medication effective if you lose at least 5% of your starting weight, but plenty of patients lose far more. I’ve had patients lose 50, 60, even 80 pounds combining these medications with lifestyle changes.

Who should consider these medications

The FDA set specific criteria for weight-loss use. You need a body mass index (BMI) of 30 or higher, which puts you in the obesity category. If your BMI is 27 or higher and you have at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol, you may also qualify.

BMI doesn’t tell the whole story. As a cardiologist, I pay close attention to patients whose cardiovascular risk factors stand to improve with weight loss. If you have metabolic syndrome, prediabetes, sleep apnea, or a family history of heart disease, the payoff from real weight loss goes well past how you look or feel day to day. We’re talking about your long-term cardiovascular health.

I also weigh your previous attempts and your overall picture. If you’ve gone through multiple supervised diet and exercise programs without lasting results, these medications might give your body the support it needs. Some patients have hormonal or genetic factors that make traditional approaches fall short, and GLP-1 medications can level that ground.

Age plays a role too. These are approved for adults, and I find them especially useful for patients in their 40s, 50s, and 60s who are fighting the metabolic changes that make weight harder to manage with each decade. The cardiovascular benefits matter more as we age, not less.

How we adjust based on your response

Starting these medications takes a careful, stepwise approach. We don’t jump to the full dose, because that would set you up for side effects you can’t tolerate. Instead we use a titration schedule, raising your dose every few weeks so your body can adjust.

For semaglutide (Wegovy), we start at 0.25 mg once weekly for four weeks, then move to 0.5 mg for four weeks, then 1.0 mg, then 1.7 mg, and finally 2.4 mg, the full therapeutic dose for weight loss. The whole process takes about 16 to 20 weeks. I know that sounds long, but the slow climb keeps side effects down and gives your body time to adapt.

During those weeks I’m watching a few things. How well are you tolerating the medication? Is nausea, vomiting, or another digestive issue interfering with your daily life? Are you getting the appetite reduction and early weight loss we’d expect? And is anything concerning showing up in your symptoms or your lab work?

If a dose isn’t sitting well, we might hold there longer or step back to the previous dose for a while. There’s no rush. The goal is the dose that gives you the most benefit with side effects you can live with. Some patients do beautifully on lower doses, and others need the full amount to see real results.

Common misconceptions

Let me clear up a few things I hear in clinic all the time. These aren’t appetite suppressants in the old sense. They’re not stimulants like the diet pills of the past. They work by strengthening your body’s own appetite regulation, which is why the effect feels more natural and lasts.

They’re also not addictive. They don’t create dependency or withdrawal. When you stop them, though, your appetite and weight will tend to drift back toward where they were before. That’s why we usually plan on long-term use, the same way we treat high blood pressure or high cholesterol.

Some patients assume the medication will do everything for them. It does cut appetite and make it easier to eat less, but you still have to make good food choices and stay active. The medication hands you the tools. You still have to use them.

I also hear that losing weight with medication “doesn’t count,” that it’s somehow lesser than dieting your way there. That idea is unhelpful and wrong. If you have a medical condition that makes a healthy weight extremely hard to reach, treating it with an effective medication isn’t cheating. It’s good medical care.

The limitations

These medications help a lot of patients, and they still have real limits. They don’t work for everyone. As I said, about 15 to 20% of patients don’t get clinically significant weight loss even with optimal dosing and lifestyle changes.

The loss, while substantial, may not get you to your goal weight. If you start at a BMI of 40 and lose 20% of your body weight, you’ll see tremendous health benefits, and you may still land in the overweight or even obese range. We have to balance honest expectations against meaningful improvement, and meaningful improvement is worth a lot.

Side effects are manageable for most people and limiting for some. The gastrointestinal effects, nausea, vomiting, and diarrhea, usually ease over time but can stick around. There are rarer but more serious possibilities too, including pancreatitis and gallbladder problems, that we monitor for.

Cost and insurance remain real barriers. These medications are expensive, often $1,000 or more per month without coverage. More insurance plans are starting to cover them, but the criteria can be tight and coverage still isn’t universal.

When not to use them

A few situations rule these medications out entirely. If you have a personal or family history of medullary thyroid carcinoma, a rare thyroid cancer, or multiple endocrine neoplasia syndrome type 2 (MEN 2), they aren’t safe for you.

If you’ve had a severe allergic reaction to any GLP-1 medication or its components, you shouldn’t use them. Pregnancy and breastfeeding are also off-limits, since we don’t have adequate safety data there.

I’m cautious in patients with a history of severe gastroparesis (delayed stomach emptying) or active gallbladder disease. Patients with a history of pancreatitis need careful evaluation, since these medications might raise the risk of a recurrence.

There’s a practical side too. If you’re not ready to make any lifestyle changes, or if you’re expecting the medication to do something it can’t, it may not be the right time to start. These work best as one piece of a full approach to weight.

What to expect, honestly

I want to be straight with you about the early going. The first few weeks can be rough while your body adjusts. Many patients feel nauseated, especially in the hour or two after an injection. It usually improves, but it can be discouraging at first.

Foods you used to love may turn unappealing or even make you feel sick. Rich, fatty, or sweet foods tend to be the first to go. That helps with weight loss, and it can take some getting used to socially and at the table.

The appetite drop can be steep. Some patients worry they’re not eating enough or that they’re sliding into an eating disorder. That’s usually not the case, and it’s worth being deliberate about getting good nutrition even when you’re eating much smaller amounts.

Weight loss isn’t a straight line. You might drop several pounds one week and nothing the next. Some patients even gain a little early on as their body adjusts. That’s normal, and it doesn’t mean the medication isn’t working.

Energy can swing as you adapt to eating less and your body changes. Some patients feel more energetic as the weight comes off and their health improves. Others feel tired at first while they adjust to fewer calories.

How this fits your cardiovascular care

As your cardiologist, I care most about how weight loss with these medications fits the rest of your heart health. The benefits run well past the number on the scale. Weight loss with GLP-1 medications usually improves blood pressure, often enough that we can lower or stop a blood pressure medication.

Blood sugar control improves too, even in patients without diabetes. That matters, because better insulin sensitivity lowers your risk of developing type 2 diabetes and cardiovascular disease. I often see hemoglobin A1c, a measure of long-term blood sugar control, improve even in non-diabetic patients.

Cholesterol usually moves in the right direction. LDL cholesterol, the “bad” kind, often drops, while HDL cholesterol, the “good” kind, may rise. Triglycerides frequently improve a great deal.

Sleep apnea, if you have it, often improves with weight loss, which means better sleep and less strain on the heart. Inflammation markers in the blood, which track with higher cardiovascular risk, usually fall as patients lose weight.

I coordinate these medications with whatever else you’re on. If you take blood pressure medications, we may need to cut doses as you lose weight so your pressure doesn’t drop too low. If you have diabetes and take insulin or other diabetes medications, we’ll watch your blood sugars closely to prevent hypoglycemia.

Where this is heading

Medical weight loss is moving fast, and a few developments have me genuinely interested. Tirzepatide (Zepbound), which targets both GLP-1 and GIP receptors, is producing even larger weight loss than the original GLP-1 medications. Some patients in clinical trials lost 25% or more of their body weight.

Oral forms are in development, which could do away with the weekly injection. Combination medications are also being studied that might deliver better results or fewer side effects.

Research is looking at these medications for conditions beyond diabetes and obesity. There’s growing evidence they may have direct cardiovascular benefits independent of weight loss, possibly lowering heart attack and stroke risk even in patients who don’t shed much weight.

We’re learning how to use them better too. Studies are testing the best ways to pair them with lifestyle changes, other medications, and surgery for patients with severe obesity. And the cost should come down over time as more options arrive and generics develop, which should widen access for patients who’d benefit.

How to approach the decision

If you’re thinking about GLP-1 medications, start with an honest look at your past attempts and your current health. Have you tried structured diet and exercise programs with professional guidance? What happened, and what made it hard to hold any weight loss you managed?

Think about your readiness for change. These medications make eating less easier, and you’ll still need ongoing lifestyle changes for the best results. Are you prepared to adjust your eating, move more, and keep your follow-up appointments?

Look at your support system. Do you have family or friends who’ll back your efforts? Are there people who might undermine them, on purpose or not? Both shape how this goes.

Money matters. Check with your insurance about coverage for weight-loss medications. Even if it’s a no at first, this is changing quickly and coverage may open up. Weigh the cost against your overall health spending and the savings that come from better health down the line.

Finally, find a clinician who has experience with these medications and will work with you as a partner. This isn’t a “take this pill and come back in six months” treatment. It needs monitoring, dose adjustments, and lifestyle counseling along the way.

Making the decision that’s right for you

This is a personal decision, and it should rest on your own health, your goals, and your circumstances. These medications are a powerful tool. They’re not right for everyone, and they don’t replace healthy lifestyle choices.

If you have significant weight to lose and have struggled with the usual approaches, if you have weight-related conditions that could improve with weight loss, and if you’re ready to treat this as a long-term commitment, these medications might be an excellent option for you.

What makes the difference is going in with realistic expectations and a clear understanding of both the benefits and the limits. Work with someone who can guide you through the process, track your progress, and help you handle whatever comes up.

The goal isn’t only weight loss. It’s better health, better quality of life, and lower risk of serious disease. If GLP-1 medications can help you get there safely, they’re worth considering as part of your overall plan.

The most important piece is that you decide based on accurate information and real medical guidance. These medications have helped many of my patients lose weight they never thought they could. They aren’t magic. They’re medical tools, and they work best alongside commitment, lifestyle changes, and steady professional support.

References

1. Davies, Melanie J., Vanita R. Aroda, Billy S. Collins, et al. “Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetes Care 45, no. 11 (2022): 2753-2786.

2. Elmaleh-Sachs, Alyssa, Judith L. Schwartz, Carolyn T. Bramante, et al. “Obesity Management in Adults: A Review.” JAMA 330, no. 20 (2023): 2000-2015.

3. Moiz, Aliya, Kristian B. Filion, Hoda Toutounchi, et al. “Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials.” Annals of Internal Medicine 178, no. 2 (2025): 199-217.

4. Grunvald, Eduardo, Raj Shah, Ruben Hernaez, et al. “AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.” Gastroenterology 163, no. 5 (2022): 1198-1225.

5. Yanovski, Susan Z., and Jack A. Yanovski. “Approach to Obesity Treatment in Primary Care: A Review.” JAMA Internal Medicine 184, no. 7 (2024): 818-829.

6. Liu, Yuxin, Bo Ruan, Haoyu Jiang, et al. “The Weight-Loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-Diabetic Individuals With Overweight or Obesity: A Systematic Review With Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.” The American Journal of Clinical Nutrition 118, no. 3 (2023): 614-626.

7. Gilbert, Oneida, Martha Gulati, Ty J. Gluckman, et al. “2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health: A Report of the American College of Cardiology Solution Set Oversight Committee.” Journal of the American College of Cardiology (2025): S0735-1097(25)06504-0.

8. Jastreboff, Ania M., Louis J. Aronne, Nadia N. Ahmad, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine 387, no. 3 (2022): 205-216.

9. Wilding, John P.H., Rachel L. Batterham, Salvatore Calanna, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine 384, no. 11 (2021): 989-1002.

10. Pi-Sunyer, Xavier, Astrup Arne, Ken Fujioka, et al. “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.” New England Journal of Medicine 373, no. 1 (2015): 11-22.